VERA Stock — Vera Therapeutics Inc.: Cash, EV, Pipeline

Share price

$34.00

Market cap

$2,450.2M

Cash

$499.2M

Enterprise value

$2,026.2M

Balance sheet

Cash	$499.2M
Debt	$75.2M
Net cash	$424.0M
Enterprise value	$2,026.2M
Basic shares	71.8M shares
Fully diluted shares	76.7M shares
Fully diluted market cap	$2,607.7M
Cash per share	$6.95

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VERA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Atacicept	Phase 2	IgA Nephropathy (IgAN); Berger Disease	—
Dec 13, 2027 - Jan 24, 2028	Atacicept	Phase 2	pMN; IgAN; Nephrotic Syndrome	—
Jul 2 - Aug 13	Atacicept 150 mg	Phase 2	IgA Nephropathy (IgAN); Renal and Urinary Disorders; Berger Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

atacicept

Approved · Active Modality: TACI-Fc fusion protein

Aliases TRUTAKNA

Target BAFF / APRIL

Partnerships Ares/Merck KGaA: worldwide exclusive rights to atacicept (Ares Agreement)

Indications

IgA nephropathy (IgAN) (Approved)
Primary membranous nephropathy (pMN) (Phase 2)
Focal segmental glomerulosclerosis (FSGS) (Phase 2)
Minimal change disease (MCD) (Phase 2)
IgA vasculitis nephritis (Phase 2)

Catalysts

— Q3 2026
— Q4 2026 / 2027
— Q4 2026
— 2026

Status note Lead product. FDA granted accelerated approval for IgAN on July 7, 2026. ORIGIN 3 Phase 3 trial ongoing (104-week double-blind); final efficacy analysis supports sBLA for full approval. Phase 2 PIONEER basket trial evaluating atacicept in expanded IgAN and other autoimmune glomerular diseases.

MAU868

Phase 2 · Active Modality: monoclonal antibody

Target BKV (BK polyomavirus)

Partnerships Novartis: worldwide exclusive development and commercial rights (Novartis License)

Indications

BK viremia in kidney transplant recipients (Phase 2)

Status note Phase 2 completed in 2022. Evaluating strategies for continued development, including a potential next clinical trial, following FDA feedback.

VT-109

Preclinical · Active Modality: fusion protein

Target BAFF / APRIL

Partnerships Stanford University: global rights acquired January 2025 (Stanford Agreement)

Indications

B-cell-mediated diseases (Preclinical)

Status note Next-generation BAFF/APRIL-targeting fusion protein in preclinical development.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Atacicept
Lead indication	IgA Nephropathy
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04716231	Phase 3	Active, not recruiting	Sponsor	VERA	—	IgA Nephropathy; Berger Disease	—
NCT06983028	Phase 2	Recruiting	Sponsor	VERA	—	pMN; IgAN; Nephrotic Syndrome	—
NCT06674577	Phase 2	Enrolling by invitation	Sponsor	VERA	—	IgA Nephropathy (IgAN); Renal and Urinary Disorders; Berger Disease	—
NCT07020923	Phase 2	Active, not recruiting	Sponsor	VERA	—	IgA Nephropathy (IgAN); Berger Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Vera Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	2,200,000	+2,200,000	4.06%	2026-08-14
Braidwell LP	564,724	+40,900	0.90%	2026-08-14
OrbiMed Advisors	369,596	no change	0.30%	2026-08-14
Ikarian Capital	310,000	+110,000	2.18%	2026-08-14
ADAR1 Capital Management	18,322	+2,289	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VERA — Vera Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders